Organon & Co. reported first‑quarter 2026 results on April 30, 2026, with revenue of $1.460 billion—a 4% year‑over‑year decline and a 9% drop on an adjusted foreign‑exchange basis. Adjusted earnings per share were $0.71, missing the consensus estimate of $0.83 by $0.12.
The decline in revenue was driven largely by a 16% drop in the Women’s Health segment as‑reported (19% ex‑FX), driven by a 28% decline in U.S. Nexplanon sales and a 21% ex‑FX decline in global sales. The Established Brands portfolio fell 1% as‑reported (7% ex‑FX). In contrast, the General Medicines/Biosimilars segment grew 23% as‑reported (21% ex‑FX), providing a tailwind to the overall results.
Operating margin contracted, reflecting pricing pressure, a shift in product mix, and adverse foreign‑exchange movements. A $301 million goodwill impairment recorded in the prior year contributed to the earnings miss. Organon’s net‑leverage target remains below 4× by year‑end 2025, a goal that underpins its deleveraging strategy.
Management reiterated its objective to maintain 2026 operational performance in line with 2025, noting that the revenue foregone from the sale of the JADA® system will be offset by favorable currency translation, resulting in constant‑currency revenue growth that is flat with the prior year pro‑forma. Guidance for 2026 remains flat on revenue and adjusted EBITDA at $1.9 billion, and the company has declared a quarterly dividend of $0.02 per share payable in June 2026.
Investors’ attention was largely focused on the announced acquisition by Sun Pharmaceutical Industries Limited, which is expected to close in early 2027. The earnings miss was not the primary driver of market reaction, and the company has suspended quarterly earnings calls and guidance in light of the pending merger.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.